Evaluation of homocysteine and asymmetric dimethyl arginine (adma)levels in hypertensive disorders of pregnancy.

Sasidharan, Latha; Sampson, Ursula; Ponnazhagan, K.; Asokan, Keloth Manapatt; Chakravarthy, K. Manas

Background: Hypertensive disorders of pregnancy (HDP) are prevalent complications, contributing significantly to maternal and perinatal morbidity. Elevated levels of homocysteine and asymmetric dimethylarginine (ADMA) may be linked to the severity of these conditions. Method: This study evaluated homocysteine and ADMA levels in 210 pregnant women, including 110 with HDP and 100 normotensive controls. Blood samples were collected, and biomarker levels were measured using enzyme-linked immunosorbent assay (ELISA). Statistical analysis was performed to compare levels between groups and assess correlations with hypertension severity. Results: The hypertensive group showed significantly higher mean homocysteine (14.3 ± 3.5 μmol/L) and ADMA (0.78 ± 0.21 μmol/L) levels compared to controls (8.7 ± 2.1 μmol/L and 0.49 ± 0.18 μmol/L, respectively; p < 0.001). Among subgroups, mean homocysteine levels trended upward from gestational hypertension to eclampsia, but without statistical significance (p = 0.075). The incidence of adverse pregnancy outcomes, including preterm birth and low birth weight, was significantly higher in the hypertensive group. Conclusion: Elevated homocysteine and ADMA levels are associated with the severity of HDP, suggesting their potential as biomarkers for risk assessment and management in pregnant women.

LOW birth weight; ASYMMETRIC dimethylarginine; PREGNANCY outcomes; ENZYME-linked immunosorbent assay; PREGNANT women

Pravara Medical Review, 2024, Vol 16, Issue 4, p61

0975-0533

Academic Journal

10.36848/PMR/2024/044000.10777